Shire plc has licensed three drugs in development from Amicus Therapeutics. The non-U.S. rights cover Amigal for Fabry disease (Phase II), Plicera for Gaucher disease (Phase II) and AT2220 for Pompe disease (Phase I). Shire’s chief executive officer, Matthew Emmens, remarked, “Amicus’ pharmacological chaperone compounds have the potential to be an excellent addition to our current enzyme replacement therapy business, which includes Replagal for Fabry disease, Elaprase for Hu...